3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
2
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
24
Lymphoma, Non-Hodgkin
17
Lymphoma, Follicular
14
Lymphoma, Mantle-Cell
9
Lymphoma
6
Lymphoma, B-Cell, Marginal Zone
5
Recurrence
3
Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, B-Cell
2
Leukemia
2
Hematologic Diseases
2
Waldenstrom Macroglobulinemia
1
Tumor Lysis Syndrome
1
Multiple Myeloma
1
Lymphoma, T-Cell, Peripheral
1
Leukemia, B-Cell
1
Immunoblastic Lymphadenopathy
1
Hodgkin Disease
1
Chromosome 17 deletion
1
Interventions
Vincristine
7
Cyclophosphamide
7
10-propargyl-10-deazaaminopterin
7
Prednisone
6
Doxorubicin
6
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
5
romidepsin
3
belinostat
3
Gemcitabine
3
liposomal doxorubicin
2
duvelisib
1
Vitamin B 12
1
MLN 8237
1
Folic Acid
1
Etoposide
1
E7777 fusion protein
1
Decitabine
1
CHOP protocol
1
Brentuximab Vedotin
1
Bendamustine Hydrochloride
1
BAEC protocol
1
Alemtuzumab
1
1-dodecylpyridoxal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, T-Cell, Peripheral
×
Bendamustine Hydrochloride
×
Clear all
NCT06522737
2026-04-06
TERZO
SecuraBio
Phase 3
Recruiting
124 enrolled